AGM approves bonus shares and capital increase Hennigsdorf, 24 July 2015 – The Annual General Meeting of Deutsche Biotech Innovativ AG ("DBI"), which was held in Berlin yesterday, has approved all resolutions proposed by the Management Board and the Supervisory Board of the company with 100 percent.
Hennigsdorf, 24 July 2015 – The Annual General Meeting of Deutsche Biotech Innovativ AG ("DBI"), which was held in Berlin yesterday, has approved all resolutions proposed by the Management Board and the Supervisory Board of the company with 100 percent. Overall, 98.91 percent of the share capital of the Company were represented.
In particular, the shareholders approved the issue of bonus shares by a capital increase from company funds in the ratio 1:1. Thus, by issuing 447,300 new shares the share capital of the Company will double from currently EUR 447,300.00 to EUR 894,600.00, divided into 894,600 no-par value bearer shares.
In addition, the Annual General Meeting resolved a capital increase against cash contributions by issuing up to 596,400 new shares. The subscription price will be determined later and the shares will be offered to the shareholders for a period of at least two weeks. Any shares not subscribed after the end of the subscription period may be offered to the shareholders and/or interested investors for subscription or purchase. The Management Board was authorized to determine with the approval of the Supervisory Board the further details of the capital increase. This capital increase is expected to be carried out in the second half of 2015.
With the funds generated from the capital increase DBI plans to advance its drug development. This includes in particular the execution of Phase I and II clinical trials with the "First-in-Class" sepsis drug Adrecizumab and the finalization of the preclinical studies for the drug DB1RA for prevention of breast cancer.
"We at DBI develop drugs for unmet medical needs. The funds from the capital increase shall allow us to build up and expand our drug pipeline in the future furthermore," says Dr. Bernd Wegener, CEO of DBI.
Deutsche Biotech Innovativ AG
Ms. Susanne Wallace
Tel.: +49 (0)3302 20 77 811
Kirchhoff Consult AG
Ms. Anja Ben Lekahl
Tel.: +49 (0)40 609 186 55